Ticker LaunchReverse merger · Completed · LSTA
Marea Therapeutics, Inc.
Reverse merger with Lisata Therapeutics, Inc. (LSTA)
Marea Therapeutics, Inc. merged into Lisata Therapeutics, Inc. (LSTA), a clinical-stage pharmaceutical company after strategic alternatives review, in a reverse merger that takes the private company public. The agreement was signed and the deal closed on the same day, Sep 17, 2026. The combined company trades as Lisata Therapeutics, Inc. (LSTA) on Nasdaq.
Lisata Therapeutics develops first-in-class antibody medicines for cardioendocrine diseases through its acquired subsidiary Marea Therapeutics. Lead candidates are MAR001/005 in Phase 2b for severe hypertriglyceridemia and MAR002 advancing to Phase 2 in acromegaly.
- Status
- Completed
- Private company
- Marea Therapeutics, Inc.
- Public company
- Lisata Therapeutics, Inc. (LSTA)
- Public company business before
- clinical-stage pharmaceutical company after strategic alternatives review
- Announced
- Signed and closed the same day
- Closed
- Sep 17, 2026
- Combined company
- Lisata Therapeutics, Inc. (LSTA)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- 8-K and press release: acquisition of Marea and $225M private placement Sep 17, 2026
- All filings on EDGAR CIK 320017
Other completed reverse mergers
- Autonomous Power Corporationinto Aureus Greenway Holdings Inc · Oct 1, 2026
- Open World Ltd.into VerifyMe, Inc. · Sep 30, 2026
- Obsidian Therapeutics, Inc.into Galera Therapeutics, Inc. · Aug 3, 2026
- Light Across, Inc.into Sharing Economy International Inc. · Aug 2, 2026
- Yarrow Bioscience, Inc.into VYNE Therapeutics Inc. · Jul 27, 2026
- Lōkahi Therapeuticsinto Glucotrack, Inc. · Jul 14, 2026